<DOC>
	<DOC>NCT02798120</DOC>
	<brief_summary>This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.</brief_summary>
	<brief_title>P3 Long Term Safety Study of Once Daily SB204 in Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Have completed 12 weeks of treatment in NIAC301 or NIAC302 Terminated early from an SB204 Phase 3 pivotal study for any reason Have an ongoing adverse event at Week 12 visit for NIAC301 or NIAC302 that warrants stopping study drug application Have used medications or vitamins during the 12 weeks immediately preceding this study which were reported to exacerbate acne.</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>